Adverum Biotechnologies Revenue and Competitors

Location

$648.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Adverum Biotechnologies's estimated annual revenue is currently $34.3M per year.(i)
  • Adverum Biotechnologies's estimated revenue per employee is $193,750
  • Adverum Biotechnologies's total funding is $648.5M.

Employee Data

  • Adverum Biotechnologies has 177 Employees.(i)
  • Adverum Biotechnologies grew their employee count by 0% last year.

Adverum Biotechnologies's People

NameTitleEmail/Phone
1
VP, Clinical Development and Access StrategyReveal Email/Phone
2
VP, Pipeline Strategy and External InnovationReveal Email/Phone
3
VP, Nonclinical DevelopmentReveal Email/Phone
4
VP, Clinical AffairsReveal Email/Phone
5
SVP, QualityReveal Email/Phone
6
VP AccountingReveal Email/Phone
7
SVP, Manufacturing and Supply Chain ManagementReveal Email/Phone
8
Head Bioanalytical Assay DevelopmentReveal Email/Phone
9
VP Process SciencesReveal Email/Phone
10
VP ProcurementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Adverum Biotechnologies?

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

keywords:N/A

$648.5M

Total Funding

177

Number of Employees

$34.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Adverum Biotechnologies News

2022-04-20 - Adverum Biotechnologies Announces Upcoming Data ...

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company...

2022-04-06 - Adverum Biotechnologies Proceeds with IND Amendment for ...

REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company...

2022-03-30 - Adverum Biotechnologies Reports Fourth Quarter and Full ...

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26.9M1797%$85.5M
#2
$27.2M18121%$37M
#3
$28.4M183N/AN/A
#4
$58.2M19663%N/A
#5
$38M196-10%$254M